Director, Financial Reporting & Technical Accounting

The posting, as insitro wrote it

THE OPPORTUNITY

insitro is a physical AI company dedicated to unlocking causal human biology and accelerating the delivery of better medicines to patients. Our unique Virtual Human™ platform identifies novel, high-impact genetic intervention points, which our TherML™ platform translates into therapeutics, whether small molecules, biologics, or oligos. With multiple programs in metabolic disease and neuroscience advancing toward the clinic, we are at a pivotal inflection point.

insitro is looking for an Director, Financial Reporting & Technical Accounting, with level set by experience, to be the company’s technical accounting expert and the owner of its financial reporting. In this senior individual contributor role, you will lead the year-end audit and financial statements, account for insitro’s most complex transactions, including pharma collaboration revenue, equity financings, and stock-based compensation modifications, and own the 409A valuation, international compliance, and accounting policy. This is also a chance to help build the function: as insitro grows, you will take on ownership of SOX and SEC reporting and help expand the team, playing a central role in building a public-company-ready finance organization, with a clear path to grow in level and scope as the function expands.

You will be joining a department that brings together Accounting Operations, FP&A, and Procurement. That structure gives this role visibility into each transaction from the contract and purchase order through to the financial statements. You will partner closely with Strategic Finance on forecasts and on Executive Leadership Team and Board materials. Corporate Development and Legal will also bring you in early on partnerships, financings, and equity matters, so the accounting implications are understood before terms are finalized. Our team is lean, collaborative, and hands-on, with a builder’s mindset. We are high-performing and considered a trusted partner across the company. We are also rebuilding our workflows with Claude and other AI tools, and you will help shape how reporting and technical accounting get done.

This position is based at our South San Francisco headquarters, reports to the SVP, Accounting & Financial Operations, and works onsite three days per week as part of our in-person hybrid model.

RESPONSIBILITIES

Financial Reporting

• Own the Financial Statements: Direct the annual audit and financial statement process, preparing US GAAP financial statements and footnote disclosures that are accurate, timely, and fully supported
• Run the Audit: Serve as the primary point of contact for our external auditors, leading audit planning, the PBC list, tie-outs, disclosure checklists, and resolution of audit comments
• Lead the Disclosure Committee: Own and lead the Disclosure Committee, including setting the agenda, running the meetings, gathering and assessing potential disclosure items from across the company, and documenting conclusi

[…]
provides transport to and from our South San Francisco HQ from locations all around the Bay Area

insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.

We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.

#LI-Hybrid

Please be aware of recruitment scams: we never request payments, all recruitment communications are from @insitro.com http://insitro.com, and if in doubt, contact us at info@insitro.com.

About insitro

insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com http://www.insitro.com.